Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway

Biomedicine and Pharmacotherapy

Volumn 67, Issue 5, 2013, Pages 399-405

  Kamran, Mohammad Zahid ^a   Gude, Rajiv P ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Angiogenesis; Melanoma; Metastasis; Pentoxifylline; STAT3

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 6; DNA; JANUS KINASE 1; JANUS KINASE 2; PENTOXIFYLLINE; PROTEIN BCL XL; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA BINDING; DOSE RESPONSE; DRUG CYTOTOXICITY; FEMALE; GENE PRODUCT; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PHYSIOLOGIC; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878360680     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.03.020     Document Type: Article

References (33)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
3. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
4. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954.
5. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999, 59:5059-5063.
6. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., et al. Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997, 94:3801-3804.
7. Schlessinger K., Levy D.E. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005, 65:5828-5834.
8. Frampton J.E., Brogden R.N. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995, 7:480-503.
9. Gude R.P., Ingle A.D., Rao S.G.A. Inhibition on lung homing of B16F10 by pentoxifylline, microfilament depolymerising agent. Cancer Lett 1996, 106:171-176.
10. Goel P.N., Gude R.P. Unravelling the antimetastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells. Mol Cell Biochem 2011, 358:141-151.
11. Kamran M.Z., Gude R.P. Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. Biomed Pharmacother 2012, 66:617-626.
12. 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Res 2010, 70:4045-4053.
13. Ambrus J.L., Ambrus C.M., Toumbis C.A., Forgach P., Karakousis C.P., Niswander P., et al. Studies on tumor induced angiogenesis. J Med 1991, 22:355-369.
14. Futakuchi M., Ogawa K., Tamano S., Takahashi S., Shirai T. Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci 2004, 95:18-24.
15. Hernandez-Flores G., Ortiz-Lazareno P.C., Lerma-Diaz J.M., Dominguez-Rodriguez J.R., Jave-Suarez L.F., Aguilar-Lemarroy A.C., et al. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. BMC Cancer 2011, 11:483.
16. Lehmann U., Schmitz J., Weissenbach M., Sobota R.M., Hortner M., Friederichs K., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003, 278:661-671.
17. Bard-Chapeau E.A., Li S., Ding J., Zhang S.S., Zhu H.H., Princen F., et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011, 19:629-639.
18. Liu L., McBride K.M., Reich N.C. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proc Natl Acad Sci U S A 2005, 102:8150-8155.
19. Yang J., Chatterjee-Kishore M., Staugaitis S.M., Nguyen H., Schlessinger K., Levy D.E., et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005, 65:939-947.
20. Hoeben A., Landuyt B., Highly M.S., Wildiers H., Oosterom A.T., de bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580.
21. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
22. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003, 22:319-329.
23. Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., et al. Targeting STAT3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24:5552-5560.
24. Amirkhosravi A., Meyer T., Warnes G., Amaya M., Malik Z., Biggerstaff J.P., et al. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost 1998, 80:598-602.
25. Knizetova P., Ehrmann J., Hlobilkova A., Vancova I., Kalita O., Kolar Z., et al. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 2008, 7:2553-2561.
26. Semenza G.L. Targeting Hif-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
27. Oh M.K., Park H.J., Kim N.H., Park S.J., Park I.Y., Kim I.S. Hypoxia-inducible factor-1alpha enhances haptoglobin gene expression by improving binding of STAT3 to the promoter. J Biol Chem 2011, 286:8857-8865.
28. Gahlot S., Khan M.A., Rishi L., Majumdar S. Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Biochem Pharmacol 2010, 80:1650-1661.
29. Groner B., Lucks P., Borghouts C. The function of STAT3 in tumor cells and their microenvironment. Semin Cell Dev Biol 2008, 19:341-350.
30. Wallner L., Dai J., Escara-Wilke J., Zhang J., Yao Z., Lu Y., et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006, 66:3087-3095.
31. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17:6083-6096.
32. Regis G., Pensa S., Boselli D., Novelli F., Poli V. Ups and downs: the STAT1: STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008, 19:351-359.
33. Bill M.A., Fuchs J.R., Li C., Yui J., Bakan C., Benson D.M., et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010, 9:165.